PDF factsheet
      Z

multi target TKI in renal-cell carcinoma (advanced) for all type of patients, clinical trials results

apitolisib versus everolimus
Powles, 2014

versus
axitinib versus sorafenib
AXIS (Rini), 2011
NCT00678392
axitinib
versus
second-line therapy in patients with metastatic renal cell cancer
Qin, 2012

versus
BNC105P + everolimus versus everolimus
Disruptor-1,

versus
cabozantinib versus everolimus
METEOR, 2015
NCT01865747
cabozantinib at a dose of 60 mg daily
versus
everolimus at a dose of 10 mg daily
patients with renal-cell carcinoma that had progressed after VEGFR-targeted therapyopen-label
cabozantinib versus sunitinib
CABOSUN, 2017
NCT01835158
cabozantinib (60 mg once per day)
versus
sunitinib (50 mg once per day; 4 weeks on, 2 weeks off).
untreated clear cell mRCC and Eastern Cooperative Oncology Group performance status of 0 to 2 and were intermediate or poor risk per International Metastatic Renal Cell Carcinoma Database Consortium criteriaopen-label
dovitinib versus sorafenib
GOLD,
NCT01223027
dovitinib (500 mg orally according to a 5-days-on and 2-days-off schedule)
versus
sorafenib (400 mg orally twice daily)
patients with clear cell metastatic renal cell carcinoma who received one previous VEGF-targeted therapy and one previous mTOR inhibitor open-label
pazopanib versus placebo
Sternberg, 2010
pazopanib
versus
placebo
treatment-naive and cytokine-pretreated patients with advanced renal cell carcinomadouble-blind
VEG105192, 2010
NCT00334282

versus
treatment-naive and cytokine-pretreated patients with advanced renal cell carcinoma
pazopanib versus sunitinib
COMPARZ, 2013
NCT00720941
continuous dose of pazopanib (800 mg once daily)
versus
sunitinib in 6-week cycles (50 mg once daily for 4 weeks, followed by 2 weeks without treatment)
patients with clear-cell, metastatic renal-cell carcinoma, first line
sorafenib versus interferon alpha
Escudier, 2009
oral sorafenib 400 mg twice daily
versus
subcutaneous IFN--2a 9 million U three times weekly
patients with untreated, advanced renal cancer.
sorafenib versus placebo
TARGET, 2007
NCT00073307
continuous treatment with oral sorafenib (at a dose of 400 mg twice daily)
versus
placebo
patients with renal-cell carcinoma that was resistant to standard therapy
Ratain, 2006

versus
patients with metastatic renal cell carcinoma
sunitinib versus interferon alpha
Motzer, 2007
NCT00083889
repeated 6-week cycles of sunitinib (at a dose of 50 mg given orally once daily for 4 weeks, followed by 2 weeks without treatment)
versus
interferon alfa (at a dose of 9 MU given subcutaneously three times weekly).
patients with previously untreated, metastatic renal-cell carcinoma
sunitinib versus sorafenib
SWITCH,
NCT00732914

versus
tivozanib versus sorafenib
TIVO-1, 2013
NCT01030783
tivozanib
versus
sorafenib
initial targeted therapy in patients with metastatic renal cell carcinoma

  Options


in first

in second

  Filter